We are live on ! Find out more
LUMO

Lumos Pharma, Inc. Common Stock
LUMO

Delisted

LUMO was delisted on the 11th of December, 2024.

Back to rankings

88 hedge funds and large institutions have $353M invested in Lumos Pharma, Inc. Common Stock in 2014 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 31 increasing their positions, 29 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% more call options, than puts

Call options by funds: $35.9M | Put options by funds: $18.1M

7% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 29

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

6% less funds holding

Funds holding: 94 → 88 (-6)

10% less capital invested

Capital invested by funds: $394M → $353M (-$40.2M)

35% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 17

Holders
88
Holders Change
-6
Holders Change %
-6.38%
% of All Funds
2.53%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
11
Increased
31
Reduced
29
Closed
17
Calls
$35.9M
Puts
$18.1M
Net Calls
+$17.9M
Net Calls Change
-$878K

Top Buyers

Rank Fund Capital Flow
1
ST
Spot Trading
Illinois
+$3.44M
2
First Eagle Investment Management
First Eagle Investment Management
New York
+$3.28M
3
CNB
City National Bank
California
+$2.4M
4
Millennium Management
Millennium Management
New York
+$1.26M
5
BCM
Bluefin Capital Management
New York
+$1.22M

Top Sellers

Rank Fund Capital Flow
1
Invesco
Invesco
Georgia
-$8.55M
2
UBS AM
UBS AM
Illinois
-$7.29M
3
PC
PointState Capital
New York
-$5.54M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$4.21M
5
EI
EAM Investors
California
-$1.86M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$92.1M -$4.21M -20,696 -5%
First Eagle Investment Management
2
First Eagle Investment Management
New York
$34.7M +$3.28M +16,130 +12%
BFA
3
BlackRock Fund Advisors
California
$27.6M +$935K +4,599 +4%
State Street
4
State Street
Massachusetts
$23.9M +$1.14M +5,616 +6%
Franklin Resources
5
Franklin Resources
California
$23.1M -$194K -955 -1%
PC
6
PointState Capital
New York
$21.2M -$5.54M -27,222 -23%
Vanguard Group
7
Vanguard Group
Pennsylvania
$14.4M +$439K +2,157 +4%
TAM
8
Tiverton Asset Management
Delaware
$10.6M – – –
WSA
9
Wall Street Associates
California
$7.5M +$6.91K +34 +0.1%
Axa
10
Axa
France
$6.85M -$166K -818 -3%
BIT
11
BlackRock Institutional Trust
California
$6.09M +$257K +1,262 +5%
Stifel Financial
12
Stifel Financial
Missouri
$6M -$61.2K -301 -1%
EAM
13
Eventide Asset Management
Massachusetts
$5.73M – – –
Northern Trust
14
Northern Trust
Illinois
$5.7M -$178K -875 -4%
SBH
15
Segall Bryant & Hamill
Illinois
$5.56M -$381K -1,875 -7%
CNB
16
City National Bank
California
$5.22M +$2.4M +11,813 +118%
ST
17
Spot Trading
Illinois
$4.05M +$3.44M +16,940 New
Barclays
18
Barclays
United Kingdom
$3.59M +$111K +545 +4%
Susquehanna International Group
19
Susquehanna International Group
Pennsylvania
$2.78M +$506K +2,487 +27%
Geode Capital Management
20
Geode Capital Management
Massachusetts
$2.62M +$414K +2,035 +23%
Bank of New York Mellon
21
Bank of New York Mellon
New York
$2.61M -$161K -793 -7%
GC
22
Guggenheim Capital
Illinois
$2.53M -$207K -1,018 -9%
DCM
23
Driehaus Capital Management
Illinois
$2.09M +$68.3K +336 +4%
KCM
24
Knoll Capital Management
Florida
$2.06M – – –
JG
25
Jefferies Group
New York
$2.06M +$529K +2,600 +43%
1
2 3 4 5

LUMO Hedge Fund Activity: Q2 2014 in Review

88 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q2 2014, worth a combined $353M — down 10% from $394M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of LUMO and 11 opened new positions — a net loss of 6 holders — while 29 trimmed existing stakes and 31 added.

The largest buyer was Spot Trading, opening a new position worth an estimated $3.44M. The largest seller was Invesco, exiting entirely with an estimated $8.55M sold.

  • 88 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q2 2014, down from 94 in Q1 2014.
  • Funds reported $353M of Lumos Pharma, Inc. Common Stock stock for Q2 2014, down 10% quarter-over-quarter.
  • 11 funds opened new Lumos Pharma, Inc. Common Stock positions in Q2 2014 and 17 closed out, a net change of -6 holders.
  • The largest Lumos Pharma, Inc. Common Stock buyer in Q2 2014 was Spot Trading, an estimated $3.44M added.
  • The largest Lumos Pharma, Inc. Common Stock seller in Q2 2014 was Invesco, an estimated $8.55M sold.

Based on aggregated 13F filings for Q2 2014.